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Abstract
Of the estimated 565,650 people in the U.S. who will die of cancer in 2008, almost all will have metastasis. Breast, prostate,
kidney, thyroid and lung cancers metastasize to the bone. Tumor cells reside within the bone using integrin type cell
adhesion receptors and elicit incapacitating bone pain and fractures. In particular, metastatic human prostate tumors
express and cleave the integrin A6, a receptor for extracellular matrix components of the bone, i.e., laminin 332 and laminin
511. More than 50% of all prostate cancer patients develop severe bone pain during their remaining lifetime. One major
goal is to prevent or delay cancer induced bone pain. We used a novel xenograft mouse model to directly determine if bone
pain could be prevented by blocking the known cleavage of the A6 integrin adhesion receptor. Human tumor cells
expressing either the wildtype or mutated A6 integrin were placed within the living bone matrix and 21 days later, integrin
expression was confirmed by RT-PCR, radiographs were collected and behavioral measurements of spontaneous and
evoked pain performed. All animals independent of integrin status had indistinguishable tumor burden and developed
bone loss 21 days after surgery. A comparison of animals containing the wild type or mutated integrin revealed that tumor
cells expressing the mutated integrin resulted in a dramatic decrease in bone loss, unicortical or bicortical fractures and a
decrease in the ability of tumor cells to reach the epiphyseal plate of the bone. Further, tumor cells within the bone
expressing the integrin mutation prevented cancer induced spontaneous flinching, tactile allodynia, and movement evoked
pain. Preventing A6 integrin cleavage on the prostate tumor cell surface decreased the migration of tumor cells within the
bone and the onset and degree of bone pain and fractures. These results suggest that strategies for blocking the cleavage
of the adhesion receptors on the tumor cell surface can significantly prevent cancer induced bone pain and slow disease
progression within the bone. Since integrin cleavage is mediated by Urokinase-type Plasminogen Activator (uPA), further
work is warranted to test the efficacy of uPA inhibitors for prevention or delay of cancer induced bone pain.
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Introduction
Of the estimated 565,650 people in the U.S. who will die of
cancer in 2008, almost all will have metastasis[1]. Breast, prostate,
kidney, thyroid and lung cancers metastasize to the bone. The
tumor cells within the bone elicit osteolytic and osteoblastic
reactions and incapacitating bone pain and fractures[2,3]. One
major goal is to prevent or delay cancer induced bone pain.
Invasive and metastatic human prostate tumors express integrin
A6B1, a receptor for extracellular matrix components of the bone,
i.e., laminin 332 and laminin 511[4–10].
Human prostate cancer is an indolent disease characterized by
progressive adhesion changes during the transition from normal
glands to prostatic intraepithelial neoplasia (PIN) to invasive
cancer[5,16–19]. Recent work has shown alteration in the normal
human prostate tissue organization and adhesion molecules during
prostate tumor progression[5,15]. Escape from the prostate gland
and invasion through the capsule is associated with poor prognosis
whereas confined disease is treatable. Alterations in adhesion
molecules and the downstream signaling consequences may
account for the stimulated invasion of tumor cells from their site
of origin. Integrins are transmembrane heterodimer cell adhesion
receptors [15]. Integrin expression within the normal prostate
gland reflects the diversity of the extracellular matrix components.
Normal patterns of integrin expression are maintained in lesions in
which normal basal cells retained and invasion has not occurred
(i.e., PIN lesions) [5,16–19]. However, within invasive carcinomas,
the majority of the integrin subunits are not observed on the tumor
cell surfaces. A notable exception to the pervasive loss of integrin
expression is persistent expression of the laminin receptors, A3
(10% of cases) and A6 (69% of cases) integrins, observed in the
invasive human prostate carcinoma obtained after radical
prostatectomy [5,17]. Studies indicate that the laminin receptors
A6B1 and A3B1 are maintained in the majority of prostate
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transition, A6B4 integrin expression is lost and A6B1 integrin
predominates in invasive human prostate cancer and in metastatic
lesions[4,6]. Numerous studies have implicated the A6 integrins in
cancer progression[20]. The extracellular ligands for A6B1 are
laminin 332 and 511, prominent constituents of human and mouse
bone marrow[7,21].
An inspection of the A6B1 integrin expression on prostate
tumor cells reveals a novel structural variant on the cell surface
called A6pB1[11,14,22]. The A6 integrin subunit is cleaved in half
at the tumor cell surface at specific amino acid residues resulting in
loss of the beta barrel domain and leaving the rest of the receptor
intact[12]. Prostate tumor cells expressing a mutated receptor that
cannot be cleaved, resulted in an inhibition of tumor cell migration
on laminin 332 under tissue culture conditions[13].
In this study, we determined if integrin cleavage would affect
tumor cell migration within a clinically relevant metastasis site,
such as bone. We used a novel xenograft mouse model of bone
pain to directly determine the effects of human tumor cells placed
within the living bone matrix on cancer induced bone pain. The
bone marrow is rich in laminin 332 (Laminin 5) and laminin 511
(Laminin 10)[8,9], the ligands for the A6B1 integrin[7]. We
further tested the influence on cancer induced bone pain since
previous work strongly implicated integrins in the maintenance of
neuropathic pain[23].
Results
Accordingly, we used the PC3N-A6-WT and PC3N-A6-RR
prostate cancer cells that express equivalent levels of the wild-type
A6 subunit (cleavable to A6p via uPA treatment) and the non-
cleavable subunit, respectively (Fig. 1a). The surface expression
levels of the receptors were equivalent as determined by Flow
Cytometry (FACS) analysis (Fig. 1b). The ability to cleave the
receptor by Urokinase-type Plasminogen Activator (uPA) and the
generation of the A6p structural variant is shown schematically
(Fig. 1c). We next tested the functional properties of A6 integrin
using a laminin 111 containing matrix, matrigel, modified to
contain laminin 332. Matrigel is a laminin rich extracellular
matrix that models physiologically relevant conditions[24]. The
PC3N-A6-WT cells migrated within matrigel in a manner that was
integrin dependent (Fig. 1d). The cells containing the uncleavable
receptor, PC3N-A6- RR, were unable to migrate in matrigel,
consistent with previous results using routine tissue culture
conditions (Fig. 1d)[13].
In order to determine the effect of human prostate cancer cells
within the bone, we adapted the Clohisy-Mantyh murine model in
which cancer cells are directly injected and sealed into the femur
of a mouse[25]. Male SCID mice were anesthetized with
ketamine/xylazine and an arthrotomy was performed exposing
the condyles of the distal femur as previously described[26]. A hole
was drilled into the femur for the injection needle to ensure
accurate placement of tumor cells within the bone. The exact
placement of the needle into the intramedullary space of the femur
was confirmed by imaging (Fig. 2a, left panel). Human prostate
tumor cells were injected into the right leg of the mouse and the
injection site sealed with dental amalgam (Fig. 2a, right panel).
We next determined the deleterious effects of tumor cells
residing within the bone using standard radiographic imaging in
live animals 21 days following surgery. All animals injected with
PC3N-A6-WT, and PC3N-A6-RR cells developed bone loss 21
days following surgery (Fig. 2b). Images consistently showed
osteolytic activity, particularly of the metaphyseal bone at the
distal (knee) end of the femur. Mice injected with the PC3N-A6-
WT cells showing dramatically more bone loss compared to those
injected with the PC3N-A6-RR cells. No bone loss was observed
in animals injected with media alone (Fig 2b). Animals injected
with the PC3N-A6-WT cells showed increased bone loss
compared to those injected with PC3N-A6-RR cells (Fig. 2b).
The radiographs were rated according to a 4 point scale in which
0 indicates normal bone and 3 indicates full thickness bicortical
bone loss (Fig. 2c). Animals injected with PC3N-A6-WT cells
showed a dramatic increase in fractures (unicortical or bicortical)
21 days following surgery compared to the PC3N-A6-RR treated
mice (Fig. 2d). These data indicate that the placement of tumor
cells within the bone containing a non-cleavable A6 integrin
results in a significant delay in the development of bone loss.
Although the imaging results provided information about severe
bone destruction, it did not give direct information about the
distribution of the tumor cells. Bone loss is a consequence in part
of tumor cells resident within the bone; an event that dramatically
affects the critical balance of osteolytic and osteoblastic activity[3].
We directly investigated the distribution of the tumor cells within
the bone using histological analysis by hemotoxylin and eosin
staining of decalcified specimens. The mouse bones were carefully
oriented for longitudinal sectioning to include observing the
epiphyseal plate as well as the distal region of the bone in the same
section (Fig. 3A, top panel). The analysis of the bones from the
tumor injected animals demonstrated presence of tumor in the
entire intramedullary space of the bone in those injected with
PC3N-A6-WT cells along with invasion into the cortical bone
(Fig. 3A, center panel). The tumor cells containing the
cleavable integrin had reached the epiphyseal plate; the bone
marrow was completely replaced. This result is consistent with the
knowledge that once prostate cancer has established itself in bone
marrow it will eventually replace the marrow, interrupting bone
homeostasis[3]. In contrast, PC3N-A6-RR injected animals
contained tumor cells in the mid-shaft region of the bone and
the tumor failed to reach the epiphyseal plate. Normal bone
marrow was present in the areas that did not contain tumor cells
(Fig. 3A, bottom panel). The tumor cells within the mid shaft
region or those that had reached the epiphyseal plate were viable
and morphologically indistinguishable. (Fig. 3A, center and
bottom panel, insets). The tumor distribution pattern was
found to be consistent in the histological analysis of all the test
animals assayed.
In order to confirm that the injected tumor cells were expressing
the mutated integrin, 21 days following injection of PC3N-A6-WT
or PC3N-A6-RR cells, the marrow was expressed from the
intramedullary space of the mouse femurs. Analysis of bone
marrow samples resulted in mRNA specific for the PC3N-A6-RR
cells in marrow from mice injected with PC3N-A6-RR, but not
PC3N-A6-WT mice. These data indicated that PC3N cells
transfected with the uncleavable A6 integrin maintained expres-
sion of the mutant integrin within the intramedullary space of the
femur and were present 21 days following injection of the cells into
the femur (Fig. 3B).
Behavioral analyses of spontaneous and evoked pain were
determined 21 days following injection of PC3N-A6-WT or
PC3N-A6-RR cells into the femur to evaluate the role of cleavage
of A6 integrin on the development of spontaneous and evoked
cancer pain behaviors. Spontaneous pain was measured by
assessing flinching of the cancer treated hind limb as previously
described[26]. Mice injected with PC3N-A6-WT cells showed
increased spontaneous flinching behavior compared to PC3N-A6-
RR treated mice which demonstrated low levels of flinching that
were comparable to control animals (Fig. 4a). Evoked pain, as
indicated by tactile allodynia, was determined by paw withdrawal
Preventing Cancer Bone Pain
PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3535Figure 1. Biochemical and migration phenotype of PC3N-A6-WT and PC3N-A6- RR cells expressing the wildtype(cleavable) and
RR(uncleavable) integrin A6, respectively. (A) The expression of the full length 6 integrin ( 6) and uPA dependent production of the 6p variant (
6p) was determined by western blot analysis. Integrin status within total cell lysates from doxycycline (Dox) or urokinase (uPA) untreated (2) and
treated (+) PC3N-A6-WT and PC3N-A6-RR cell lines was determined. (B) Surface expression of wild type and mutated integrin 6 in doxycycline induced
PC3N-A6-WT and PC3N-A6-RR cells was determined by flow cytometry. PC3N-A6-WT and PC3NA6- RR cells were incubated with primary Rat anti-
integrin A6 antibody J1B5 followed by Alexa 488 anti-rat antibody and visualized using the BD FACScan. The grey peak indicates fluorescence signal
from secondary antibody only. (C) Schematic to illustrate the cleavage of the full length form of the 6 integrin to yield the 6p variant. The definition of
the PC3N-A6-WT and PC3N-A6-RR cells with regard to integrin status is shown. (D) Integrin mediated migration of PC3N-A6-WT cells (top panels) and
PC3NA6- RR cells (bottom panels) on matrigel. The cells were placed on matrigel in the presence of a coverslip to create a cell free zone on the
matrigel surface. After cell adhesion was complete, the coverslips were removed from the matrigel surface to allow migration into the cell free zone
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PLoS ONE | www.plosone.org 3 October 2008 | Volume 3 | Issue 10 | e3535Figure 2. SCID Mouse xenograft model and quantification of bone destruction after injection of prostate cancer cells into the
femoral intramedullary space. (A) Radiographic images were taken to verify needle placement inside the intramedullary space of the femur up to
the distal third of the bone (left panel). The tumor cells were sealed into the bone (right panel). (B) Radiographic images taken at 21 days after
injections indicating bone loss either from untreated mice (Control) or mice injected with tumor cells expressing the wildtype integrin (PC3N-A6-WT)
or the mutated integrin (PC3N-A6-RR). (C) Quantification of bone loss in animals either sham injected (Control) or injected with tumor cells expressing
the wildtype integrin (PC3N-A6-WT) or the mutated integrin (PC3N-A6-RR). Bone loss was rated according to the following 5 point scale: 0=normal,
1=bone loss observed in less than half of the distal third of the bone, 2=bone loss observed in more than half of the distal third of the bone, no
fracture, 3=full thickness unicortical bone loss indicating unicortical bone fracture, 4=full thickness bicortical bone loss indicating bicortical bone
fracture. (D) The percent of mice with fracture 21 days following surgery. The number of mice in each group was twelve.
doi:10.1371/journal.pone.0003535.g002
indicated by white or black curved line. Cells migration occurred under optimal growth conditions at 37 for approximately 18 hours. Cells were either
allowed to migrate in the absence (left panels) or presence (right panels) of integrin blocking antibody AIIB2. Images were collected using a Zeiss
Axiovert microscope equipped with a 2.5X objective.
doi:10.1371/journal.pone.0003535.g001
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femur with calibrated von Frey filaments as previously de-
scribed[26]. Mice injected with the PC3NA6-WT cells showed
tactile allodynia as indicated by lowered threshold for paw
withdrawal from von Frey filaments (Fig. 4b). In contrast,
PC3N-A6-RR injected mice did not show tactile allodynia, with
paw-withdrawal thresholds similar to control animals (Fig. 4b).
Movement-evoked pain was determined by rating the limb use
during normal ambulatory movement as previously described[26].
Mice injected with PC3N-A6-WT cells developed movement
evoked pain whereas mice injected with PC3N-A6-RR cells
showed no movement-evoked pain, with limb use ratings the same
as control animals (Fig. 4c).
These data indicate that cleavage of integrin A6 influenced the
development of cancerinduced spontaneous and evoked pain
associated with bone loss and fracture. Preventing cleavage of
integrin A6 dramatically reduced bone loss and development of
cancerinduced pain. In contrast, expression of the cleavable A6
integrin increased cancerinduced bone loss and fracture with a
concurrent increase in pain behavior.
Discussion
In this study we exploited a direct injection bone model to
specifically place human prostate tumor cells directly into the
physiologically and clinically relevant bone environment, rich in
laminin 332 and 511. This allowed us to determine if blocking
production of a laminin receptor (A6pB1) would alter the ability of
the tumor cells to migrate or modify the environment within the
bone and whether this held functional significance in terms of
bone pain.
The results showed that modifying the production of the A6pB1
laminin receptor on the tumor cell surface can remarkably hinder
migration within the bone. The direct injection model allows for
the precise placement of known numbers of tumor cells within the
bone. Since the tumor cells grow equally well independent of
integrin status [13,27] (both in tissue culture and as human tumors
in mice), the data suggests that the distribution of tumor cells
within bone may be a key element influencing cancer induced
bone pain. The inability of tumor cells to reach the epiphyseal
region of the bone due to integrin status coincided with a
remarkable decrease of three distinct behavioral pain measure-
ments. While it is unknown currently whether location of tumor
cells within bone and bone pain were functionally linked, other
reports have indicated that within bone, microenvironments are
sufficiently distinct to warrant this possibility[28].
It is possible that the diminished bone pain is due to the inability
of the integrin to be cleaved, independent of the location of the
tumor cells within the bone. Integrins and cadherins are cleaved or
shed on tumor cell surfaces[29–32]. The liberated fragments of
receptors undergoing ectodomain cleavage are biologically active
and may contribute to cancer induced bone pain[33]. Further
experiments will distinguish between these possibilities.
Although bone metastases are traditionally thought to be either
osteolytic or osteoblastic, morphological analyses have revealed
that, in most patients, bone metastases have both osteolytic and
osteoblastic elements[38]. In prostate cancer patients, bone
metastases frequently show more osteoblastic phenotype, although
some patients have osteolytic lesions similar to those seen in
patients with metastatic breast cancer[38]. This research focused
on a human prostate cancer cell line that produced mostly
osteolytic bone remodeling in the mouse bone. The inability of the
integrin to be cleaved resulted in reduced bone loss and fracture.
As most bone loss and fracture are observed at the distal end of the
Figure 3. Histological examination of bone destruction, tumor
cell distribution and verification of mutated integrin expression
after injection of prostate tumor cells. (A) Hematoxylin-eosin staining
of the normal bone (control) or bone injected with PC3N-A6-WT cells (WT,
middlepanelandinset)andPC3N-A6-RRcells(RR,bottompanelandinset).
The growth plate of the bone (epiphyseal plate) is oriented at the top left
of each panel for comparison purposes. (B) RT-PCR analysis to detect
expression of the mutated 6 integrin in the bonemarrow.Twentyone days
following injection, bone marrow was harvested, RNA was extracted and
analyzed. RNA from PC3N-A6-WT cells and PC3N-A6-RR cells growing in
tissue culture was compared to the bone marrow isolated from mice
injected with PC3N-A6-WT cells (Bone marrow-WT cells) or PC3NA6- RR
cells (bone marrow-RR cells). GAPDH amplification was carried out as
control and the kB markers are as shown.
doi:10.1371/journal.pone.0003535.g003
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of the bone may have reduced the bone loss and fracture in that
area. Future studies on the role of integrins on osteoblastic bone
remodeling would be needed to determine whether altering
integrin function will also alter osteoblastic reactions in the bone.
Finally we note that cancer induced bone destruction is
associated with severely reduced quality of life stemming from
complications such as hypercalcemia, bone fracture and incapac-
itating pain. Advances in cancer detection and therapy are
extending the life expectancy of cancer patients and is increasing a
focus on improving patients’ quality of life. Both the use of the
novel xenograft mouse model for studying the prevention of
cancer induced bone pain and targeting adhesion receptors on the
tumor cell surface for the bone should significantly impact the
quality of life for patients with metastatic disease.
Materials and Methods
Human Prostate Cancer Cell Lines
The PC3N cells were transfected with plasmids containing
either the wildtype or mutated integrin A6 as previously
described[13]. The stable clones (PC3N-A6-WT expressing wild-
type integrin A6 and PC3N-A6-RR expressing the non-cleavable
integrin A6) were isolated and maintained at 37uC in a humidified
atmosphere of 95% air and 5% CO2. PC3N-A6-WT and PC3N-
A6-RR cells were grown in Iscove’s Modified Dulbecco’s Medium
(IMDM) (Gibco BRL, Gaithersburg, MD, USA) plus 10% fetal
bovine serum (FBS) in presence of 6 g/ml Blasticidin (Invitrogen
Corporation, Carlsbad, CA, USA) and 1 g/ml Zeocin (Invitrogen
Corporation, Carlsbad, CA, USA).
Antibodies and Chemicals
The antibodies were as follows: J1B5, rat monoclonal anti- A6
integrin (Dr. Caroline Damsky, University of California, San
Francisco, USA)[34]; AA6A rabbit polyclonal anti-A6 integrin
antibody[13] and AIIB2, rat monoclonal anti- B1 integrin
antibody[35] (American Type Culture Collection). Human
recombinant EGF was purchased from Invitrogen Corp.,
Carlsbad, CA, USA. Urokinase was purchased from Chemicon
(Temecula, CA, USA).
Immunoblotting
Cells were grown to confluency and then washed three times
with HEPES buffer and lysed in cold RIPA buffer plus protease
inhibitors (PMSF, 2 mM; leupeptin and aprotinin, 1 g/ml). The
lysates were briefly sonicated on ice before being suspended in 26
non-reducing sample buffer. Samples were boiled for 5 min, and
after a quick chill on ice, they were loaded onto 7.5% SDS-PAGE.
Proteins resolved in the gel were electrotransferred to Millipore
Immobilon-P polyvinylidene fluoride (PVDF) membrane (Milli-
pore, Bedford, MA, USA), incubated with Western blotting
antibodies plus secondary antibody conjugated to horseradish
peroxidase and visualized by chemiluminescence (ECL Western
Blotting Detection System, Amersham, Arlington Heights, IL,
USA).
Matrigel Migration Assay
Six well plates were coated with 1 ml Matrigel (BD Biosciences,
Bedford, MA) and supplemented with laminin 332 containing
conditioned medium from HaCaT cells in 2:1 ratio and allowed to
solidify. A sterile circular coverslip was placed in the center. Cells
were then seeded in the plates and allowed to adhere for 2 hrs at
37 degrees C. Any non-adherent cells were removed and then
coverslips were removed leaving a clear zone in the center of the
plate. The periphery of this zone was marked. Serum free media
or serum free media with blocking antibody was added to the cells
and allowed to incubate at 37 degrees C for 18 hours. 1 ng/ml
EGF was added to the media to induce migration. The cells were
observed using a Zeiss Axiovert microscope (2.56magnification)
and images were collected using a CCD camera.
Surgery
All procedures involving animals were approved by the
University of Arizona institutional animal care and use committee,
IACUC protocol #06-081. Animals were anesthetized with
ketamine/xylacine and an arthrotomy was performed exposing
the condyles of the distal femur. A hole was drilled into the femur,
and the needle was inserted into the hole. Faxitron images were
taken on 2 planes to verify needle placement inside the
intramedullary space of the femur. PC3N-A6-WT, or PC3N-A6-
RR cells, 106 in 5 ul of filtered minimal essential medium (MEM)
Figure 4. Development of cancer-induced spontaneous pain, tactile allodynia, and movement-evoked pain in animals 21 days after
surgery. (A) Spontaneous pain as measured by flinching of the ipsilateral hindlimb was determined in sham injected animals (control) or those
injected with tumor cells expressing the wild type integrin (PC3N-A6-WT) or those injected with tumor cells expressing the mutated integrin (PC3N-
A6-RR). Elevation in flinching behavior is indicative of an increased pain response. (B) Tactile allodynia as measured by paw-withdrawal from von Frey
filaments in sham injected animals (Control) or those injected with tumor cells expressing the wild type integrin (PC3N-A6-WT) or those injected with
tumor cells expressing the mutated integrin (PC3N-A6-RR). A decrease in the withdrawal threshold is indicative of an increased pain response. (C)
Movement evoked pain was observed in sham injected animals (control) or those injected with tumor cells expressing the wild type integrin (PC3N-
A6-WT) or those injected with tumor cells expressing the mutated integrin (PC3N-A6-RR).
doi:10.1371/journal.pone.0003535.g004
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MEM containing 1% BSA alone (control) was injected into the
intramedullary space of the mouse femur of the right leg and the
injection site was sealed with dental amalgam. For the following
experiments 12 animals received PC3N-A6-WT, 12 received
PC3N-A6-RR cells, and 12 animals received cell-free serum
(control).
Behavioral Pain Measures [26]
Movement-evoked pain. The mouse was placed in an empty mouse
pan and observed while walking across the pan in a continuous
motion. Limping and/or guarding behavior of the right (cancer
injected) hindlimb was rated on the following scale: 0=complete
lack of use, 1=partial non-use, 2=limping and guarding,
3=limping, 4=normal walking. Spontaneous pain. To assess
flinching and guarding behavior, animals were placed in raised
plexiglass chambers with a wire grid floor for observation of
flinching and guarding of the right hindlimb. The mice were
allowed to acclimate to the chamber for 20 minutes. Guarding
and flinching behaviors of each mouse were measured for
2 minutes. The number of flinches was counted, and the time
spent guarding the foot (the foot is lifted off of the floor) was
measured. Tactile hypersensitivity (allodynia). Paw withdrawal thresh-
olds from von Frey filaments were determined in the manner
described by Chaplan et al.[36] Paw withdrawal threshold was
determined in response to probing with calibrated von Frey
filaments. The mice were kept in suspended cages with wire mesh
floors and the von Frey filament was applied perpendicularly to
the plantar surface of the paw of the mouse until it buckled slightly,
and was held for 3–6 sec. A positive response was indicated by a
sharp withdrawal of the paw. The 50% paw withdrawal threshold
was determined by the non-parametric method of Dixon[37]. An
initial probe equivalent to 2 g was applied and if the response was
negative, the stimulus was incrementally increased until a positive
response was obtained, then decreased until a negative result was
obtained. This up-down method was repeated until 3 changes in
behavior were determined, and the pattern of positive and
negative responses was tabulated. The 50% paw withdrawal
threshold was determined as (10[Xf+k*]) /10,000, where Xf=the
value of the last von Frey filament employed, k=Dixon value for
the positive/negative pattern, and *=the mean (log) difference
between stimuli. All pain tests were performed on each animal in
the following order, movement-evoked pain, spontaneous pain
(after the 20 min acclimation period), and tactile hypersensitivity.
Determination of bone destruction
Radiographs were taken prior to the injection of the cancer cells
(baseline, BL) and 21 days following induction of bone cancer
using a Faxitron MX-20 machine at 7 uM nominal resolution with
an X-ray current of 300 uA and a voltage of 26 kV (Faxiton X-ray
Corp., Wheeling, IL). Digital radiographs were taken following
behavioral testing on 12 animals per treatment condition. Images
were captured by a digital camera and transferred to computer
and saved in digital grayscale format (TIFF). Bone loss was rated
according to the following 4 point scale: 0=normal, 1=bone loss,
no fracture, 2=full thickness unicortical bone loss indicating
unicortical bone fracture, 3=full thickness bicortical bone loss
indicating bicortical bone fracture.
Statistical analyses
Statistical comparisons between treatment groups were done
using ANOVA. Pairwise comparisons between groups were made
with Student’s t-test, multiple comparisons between groups were
done using Newman-Keuls Multiple Comparison Test. For the
rating assays, limb use and bone loss, statistical comparisons were
made using non-parametric analysis with the Mann-Whitney test.
For all analyses, significance was set at p,0.05.
Histological analysis of tumor within the bone
On day 21 post-surgery, mice were deeply anesthetized with
ketamine and perfused intracardially with 25 ml of 0.1 M PBS
followed by 25 ml of 10% neutral buffered formalin. Ipsilateral
femora were removed from 6 animals per condition and postfixed
overnight in 10% neutral buffered formalin. Femora were rinsed
in water to remove formalin prior to being placed in Decal
solution (RDO-Apex, Aurora, IL), for an hour to achieve
decalcification. Samples were dehydrated in graded ethanol
solution before carefully embedding in paraffin. They were
oriented so that the entire length of the femur could be
longitudinally sectioned. Sections 3 um thick were stained with
hematoxylin and eosin to visualize normal marrow elements and
cancer cells under bright field microscopy. The specimens were
observed using a Nikon microscope (106 magnification) and
images were collected using a CCD camera.
RT-PCR analysis of PC3N-A6-RR cells in the intramedullary
space of the femur
Bone marrow was extracted from the bones of 6 animals per
treatment condition by flushing bone cavity with PBS. Total RNA
was obtained from bone marrow and PC3N-A6-WT and PC3N-
A6-RR cells by extraction with TRIzol reagent (Invitrogen Corp.,
Carlsbad, CA, U.S.A.) according to the manufacturer’s protocol.
RNA samples were evaluated for integrity of 18S and 28S rRNA
by ethidium bromide staining of 1 mg of RNA resolved by
electrophoresis on a 1.0% agarose/formaldehyde gel. CDNA was
prepared using High Capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA, U.S.A.) as per manufacturer’s
instructions. Our primers targeted the mutation (R594R595 to
A594A595) in the PC3N- 6-RR integrin 6 and were 59-CTC TGC
TGC GCG AGT GAA TTC-39 and 59-TGT CTT GAT TTC
CTT CTC GGG T-39 (150 bp). The GAPDH primers used were
59-TGG TAT CGT GGA AGG ACT CAT GAC-39 and 59-AGT
CCA GTG AGC TTC CCG TTC AGC-39 (181 bp). PCR
products were electrophoresed on a 2% agarose gel and visualized
with Ethidium Bromide staining.
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